Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505.

@article{Kitagawa2015PaclitaxelPC,
  title={Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505.},
  author={Ryo Kitagawa and Noriyuki Katsumata and Taro Shibata and Toshiharu Kamura and Takahiro Kasamatsu and Toru Nakanishi and Sadako Nishimura and Kimio Ushijima and Masashi Takano and Toyomi Satoh and Hiroyuki Yoshikawa},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2015},
  volume={33 19},
  pages={2129-35}
}
PURPOSE In metastatic or recurrent cervical cancer, cisplatin-based chemotherapy is standard. The JCOG0505 randomized phase III trial evaluated the clinical benefits of carboplatin-based regimen. PATIENTS AND METHODS Eligible patients had metastatic or recurrent cervical cancer and had ≤ one platinum-containing treatment and no prior taxane. Patients were randomly assigned either to conventional paclitaxel plus cisplatin (TP; paclitaxel 135 mg/m(2) over 24 hours on day 1 and cisplatin 50 mg/m… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 29 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 46 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 29 references

Similar Papers

Loading similar papers…